MedTrace Logo

Impact of HPV Vaccination on Cervical High Grade Lesions in France

NCT04167501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 606

Last updated 2021-08-23

No results posted yet for this study

Summary

The objective is to estimate the prevalence of the different genotypes of human papillomaviruses (HPV) in histologically proven high-grade lesions of the cervix in patients born between 1972 and 1993. It is plan to determine if the prevalence of HPV16 and HPV18 is lower in the population born between 1983 and 1993 and potentially exposed to HPV vaccination compared to those born between 1972 and 1982 who were not exposed to vaccination. Thus the investigators should be able to determine whether the introduction of HPV vaccination in France in 2007 has had an impact on the development of high-grade lesions associated with HPV16 and HPV18.

Conditions

  • Human Papillomavirus Infection

Interventions

OTHER

biological sample analysis

HPV Prevalence analysis

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Jean-Luc PRETET, Pr · Centre Hospitalier Universitaire de Besançon

Eligibility

Min Age
27 Years
Max Age
46 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-05-01
Completion
2021-06-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04167501 on ClinicalTrials.gov